Results 71 to 80 of about 60,277 (228)

Outcomes of Cerebral Venous Thrombosis in Patients With Myeloproliferative Neoplasms from a U.S. Nationwide Hospitalization Study

open access: yes
eJHaem, Volume 7, Issue 1, February 2026.
Nikhil Vojjala   +6 more
wiley   +1 more source

CDG due to Defective Membrane Transporters: Update

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 1, January 2026.
ABSTRACT Congenital disorders of glycosylation are genetic defects in the glycoprotein and glycolipid glycan assembly and attachment. Some 200 CDG have been reported since the first clinical description in 1980. Most CDG are enzymatic deficiencies, but 13 (6.5%) are defects in the ER, Golgi apparatus (GA), and plasma membrane transporters.
D. Quelhas, C. R. Ferreira, J. Jaeken
wiley   +1 more source

Complement Pathways in Membranous Nephropathy: Complex and Multifactorial

open access: yesKidney International Reports, 2020
Vesna Brglez   +2 more
doaj   +1 more source

Cerebral venous thrombosis and secondary polycythemia in a case of nephrotic syndrome

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2016
Cerebral venous thrombosis (CVT) and polycythemia are considered as rare and life threatening complications of nephrotic syndrome. We report an unusual combination of both these complications in a case of nephrotic syndrome due to minimal change disease ...
Shankar Prasad Nagaraju   +3 more
doaj   +1 more source

Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 295-303, January 2026.
Summary The efficacy of ciclosporin (CsA) to treat transfusion‐independent non‐severe aplastic anaemia (TI‐NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI‐NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI‐NSAA aged ≥16.
Ken Ishiyama   +14 more
wiley   +1 more source

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

open access: yesEuropean Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo   +3 more
wiley   +1 more source

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature

open access: yesBMC Nephrology
Background Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events.
Ryosuke Saiki   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy